| Wolfdieter Springer, Ph.D., principal investigator |
Molecular mechanisms of PINK1-PRKN-directed mitochondrial quality control (2R01/RF1 NS085070) |
National Institute of Neurological Disorders and Stroke (NINDS) |
08/01/14-07/31/24 |
| Wolfdieter Springer, Ph.D., co-principal investigator, Center Without Walls (CWOW), Project #4 |
Synergistic interactions of amyloid-beta and alpha-synuclein in Lewy body dementia (U54 NS110435) |
National Institute of Neurological Disorders and Stroke (NINDS) |
10/01/19-06/30/24 |
| Wolfdieter Springer, Ph.D., co-principal investigator |
Mitochondrial Sirtuin 3 in Parkinson's disease (R01 N110085) |
National Institute of Neurological Disorders and Stroke (NINDS) |
06/01/19-05/30/24 |
| Wolfdieter Springer, Ph.D., principal investigator |
Determining PINK1 and PRKN enzyme activities in vivo (ID 019046) |
Michael J. Fox Foundation for Parkinson's Research (MJFF) |
04/15/21-10/15/22 |
| Wolfdieter Springer, Ph.D., principal investigator |
Early-onset Parkinson's disease is a mitochondrial disease: A nigral mitochondrial cytopathy (W81XWH-17-1-0248) |
Department of Defense (DOD) |
08/15/17-08/14/22 |
| Wolfdieter Springer, Ph.D., principal investigator |
Biomarker for mitophagy pathway activation (ID 019258) |
Michael J. Fox Foundation for Parkinson's Research (MJFF) |
12/01/20-05/31/22 |
| Wolfdieter Springer, Ph.D., principal investigator |
Validation of novel pS65-Ub antibodies (ID 17399) |
Michael J. Fox Foundation for Parkinson's Research (MJFF) |
10/01/19-04/02/22 |
| Wolfdieter Springer, Ph.D., principal investigator |
Elucidating cell type-specific PINK1 and PRKN expression in vivo (ID 021186) |
Michael J. Fox Foundation for Parkinson's Research (MJFF) |
01/03/22-01/02/22 |